

**RECEIVED
CENTRAL FAX CENTER**

JAN 03 2008 City Docket No. 019026-000110US

PTO FAX NO.: 1-571-273-8300

ATTENTION: Examiner R. P. Swartz

Group Art Unit 1645

**OFFICIAL COMMUNICATION
FOR THE PERSONAL ATTENTION OF
EXAMINER R. P. Swartz**

CERTIFICATION OF FACSIMILE TRANSMISSION


I hereby certify that the following documents in re Application of YOH-ICHI MATSUMOTO et al., Application No. 09/700,851, filed November 17, 2000 for HUMANIZED ANTIBODIES THAT RECOGNIZE VEROTOXIN II AND CELL LINE PRODUCING SAME are being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Documents Attached

1. Response to Advisory Action Before the Filing of an Appeal Brief

Number of pages being transmitted, including this page: 10

Dated: 1/3/2008


Tamara Tucker

**PLEASE CONFIRM RECEIPT OF THIS PAPER BY
RETURN FACSIMILE AT (415) 576-0300**

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, CA 94111-3834
Telephone: 650-326-2400
Fax: 650-326-2422
0229


61246961 v1

**RECEIVED
CENTRAL FAX CENTER****JAN 03 2008**

Thereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. 1-571-273-8300 on January 3, 2008.

PATENT
Attorney Docket No.: 019026-000110US
Client Ref. No.: T-400

TOWNSEND and TOWNSEND and CREW LLP

By: 
Tamara Tucker

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

YOII-ICIII MATSUMOTO et al.

Application No.: 09/700,851

Filed: November 17, 2000

For: HUMANIZED ANTIBODIES
THAT RECOGNIZE VEROTOXIN II
AND CELL LINE PRODUCING SAME

Customer No.: 20350

Confirmation No. 3540

Examiner: R. P. Swartz

Technology Center/Art Unit: 1645

**RESPONSE TO ADVISORY ACTION
BEFORE THE FILING OF AN APPEAL
BRIEF**

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Advisory Action Before the Filing of an Appeal Brief mailed on December 21, 2007, for the above-referenced application, please enter the following amendments and remarks:

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims which begins on page 3 of this paper.

Remarks begin on page 8 of this paper.